Calliditas Therapeutics (CALT) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
At the annual general meeting of Calliditas Therapeutics, key resolutions included the adoption of financial statements for 2023, re-election of board members and auditors, and the decision to not distribute dividends for the year. Additionally, the company was authorized to issue new shares, warrants, and/or convertibles up to 20% of the total shares, and to transfer its own shares, to increase financial and operational flexibility. The meeting also approved new long-term incentive programs for board members and key personnel, and updated remuneration guidelines for group management.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.